NVS vs OTLK
NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience. OTLK: Outlook Therapeutics is the developer of LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration.
Side-by-side fundamentals
| Metric | NVS | OTLK | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $153.64 | $0.52 | |
| Market cap | $286.6B | $127M | |
| Net margin FY2025, SEC XBRL | n/a | -4416.2% | |
| Gross margin FY2025, SEC XBRL | n/a | +4.0% | |
| Operating margin FY2025, SEC XBRL | n/a | -4744.3% | |
| ROE FY2025, SEC XBRL | +30.0% | n/a | |
| ROA FY2025, SEC XBRL | +12.6% | -335.9% | NVS higher |
| Dividend yield as of 2026-09-03 | +3.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.22 | 1.03 | |
| 1-year return as of 2026-10-20 close | +16.6% | -64.9% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.